Dacomitinib for EGFR+ Lung Cancer Gets EU OK Dacomitinib for EGFR+ Lung Cancer Gets EU OK

Dacomitinib has been given a positive opinion in Europe for use in the first-line treatment of EGFR+ non-small cell lung cancer.News Alerts
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news